Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line

Ouyang,Zheng-Xiao; Li,Xian-An

doi:10.3892/ol.2013.1487

Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line

Authors:
- Zheng-Xiao Ouyang
- Xian-An Li
View Affiliations

Affiliations: Department of Orthopaedics, Hunan Provincial Tumor Hospital and Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: July 24, 2013 https://doi.org/10.3892/ol.2013.1487
Pages: 970-976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to compare the combined effect of tamoxifen (TAM) and doxorubicin (ADM) with the individual effects of TAM and ADM alone on the MG63 human osteosarcoma cell line. Estrogen receptor (ER) expression was detected in the MG63 cells using reverse transcription PCR. The morphological changes during the inhibition of cell growth were observed using an inverted microscope and a 3‑(4, 5‑dimethy1‑2‑thiazol‑2‑yl)‑2,5‑diphenyl‑tetrazolium bromide (MTT) colorimetric assay following the individual or combined addition of TAM and ADM. ERα and ERβ expression was detected in the MG63 cells. The typical apoptotic cell morphology was observed in all groups, with the exception of the control group. The MTT colorimetric analysis demonstrated that the rate of inhibition of cell proliferation in the combination group was significantly increased compared with that in the other groups (P<0.05). ERα and ERβ expression was detected in the MG63 human osteosarcoma cells. TAM and ADM alone were able to inhibit cell proliferation. The combination of TAM and ADM significantly enhanced the inhibitory effect, partly through the enhanced sensitivity of the cells to ADM by TAM, which caused the inhibition of cell proliferation and apoptosis.

View Figures

View References

1	Smith MA, Ungerleider RS, Horowitz ME and Simon R: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic osteosarcoma and Ewing’s sarcoma. J Natl Cancer Inst. 83:1460–1470. 1991.PubMed/NCBI
2	Lewis IJ, Nooij MA, Whelan J, et al; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 99:112–128. 2007. View Article : Google Scholar
3	Graf N, Winkler K, Betlemovic M, et al: Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 12:1443–1451. 1994.PubMed/NCBI
4	Delepine N, Delepine G, Bacci G, et al: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer. 78:2127–2135. 1996. View Article : Google Scholar : PubMed/NCBI
5	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
6	Lewis VO, Raymond K, Mirza AN, Lin P and Yasko AW: Outcome of postradiation osteosarcoma does not correlate with chemotherapy response. Clin Orthop Related Res. 450:60–66. 2006. View Article : Google Scholar : PubMed/NCBI
7	Goldsby R, Burke C, Nagarajan R, et al: Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone turmors after 1976: follow up of a Children’s Oncology Group cohort. Cancer. 113:2597–2604. 2008.PubMed/NCBI
8	Mansky P, Arai A, Stratton P, et al: Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer. 48:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zheng A, Kallio A and Härkönen P: Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology. 148:2764–2777. 2007. View Article : Google Scholar
10	Tan CK, Chow PK, Findlay M, et al: Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. J Gastroenterol Hepatol. 15:725–729. 2000. View Article : Google Scholar : PubMed/NCBI
11	Emst M, Parker MG and Rodan GA: Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element. Mol Endocrinol. 5:1597–1606. 1991. View Article : Google Scholar : PubMed/NCBI
12	Carmichael J, DeGraff WG, Gazdar AF, et al: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
13	Braidman IP, Davennport LK, Carter DH, et al: Preliminary in situ identification of estrogen target cells in bone. J Bone Miner Res. 10:74–80. 1995. View Article : Google Scholar : PubMed/NCBI
14	Walker MJ, Chaudhuri PK, Beattie CW and Das Gupta TK: Steroid receptors in malignant skeletal tumors. Cancer. 45:3004–3007. 1980. View Article : Google Scholar : PubMed/NCBI
15	Stedman KE, Moore GE and Morgan RT: Estrogen receptor proteins in diverse human tumors. Arch Surg. 115:244–248. 1980. View Article : Google Scholar : PubMed/NCBI
16	Chen FP, Hsu T, Hu CH, Wang WD, Wang KC and Teng LF: Expression of estrogen receptors alpha and beta in human osteoblasts: identification of exon-2 deletion variant of estrogen receptor beta in postmenopausal women. Chang Gung Med J. 27:107–115. 2004.PubMed/NCBI
17	Dohi O, Hatori M, Suzuki T, et al: Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci. 99:518–523. 2008. View Article : Google Scholar : PubMed/NCBI
18	Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S and Spelsberg TC: Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol. 19:1555–1568. 2005. View Article : Google Scholar : PubMed/NCBI
19	Solakidi S, Psarra AM and Sekeris CE: Differential subcellular distribution of estrogen receptor isoforms: localization of ERalpha in the nucleoli and ERbeta in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines. Biochim Biophys Acta. 1745:382–392. 2005. View Article : Google Scholar
20	Luo XH and Liao EY: Effects of estriol on the proliferation and differentiation of human osteoblastics MG63 cells. Endocr Res. 29:343–351. 2003. View Article : Google Scholar : PubMed/NCBI
21	Berman E, Adams M, Duiguo-Osterndorf R, Godfrey L, Clarkson B and Andreeff M: Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 77:818–825. 1991.PubMed/NCBI
22	Kang Y and Perry RR: Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance. Cancer Res. 53:3040–3045. 1993.PubMed/NCBI
23	Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL and Carmichael J: Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer. 67:1189–1195. 1993. View Article : Google Scholar : PubMed/NCBI
24	O’Brian CA, Liskamp RM, Solomon DH and Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res. 45:2462–2465. 1985.PubMed/NCBI
25	Lam HY: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 118:27–32. 1984. View Article : Google Scholar : PubMed/NCBI
26	Huynh TH, Tetenes E, Wallace L and Pollak M: In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 53:1727–1730. 1993.PubMed/NCBI
27	Noguchi S, Motomura K, Inaji H, Imalka S and Koyama H: Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer. 72:131–136. 1993. View Article : Google Scholar : PubMed/NCBI
28	Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, et al: Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:4261–4264. 1992.PubMed/NCBI
29	Baral E, Nagy E and Berczi I: Modulation of natural killer cell-mediated cytotoxicity by tamoxiefn and estradiol. Cancer. 75:591–599. 1995. View Article : Google Scholar : PubMed/NCBI
30	Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH and Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett. 345:43–46. 1994. View Article : Google Scholar : PubMed/NCBI
31	Gelmann EP: Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog. J Natl Cancer Inst. 88:224–226. 1996. View Article : Google Scholar : PubMed/NCBI
32	Clarke R, van den Berg HW and Murphy RF: Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol. J Natl Cancer Inst. 82:1702–1705. 1990. View Article : Google Scholar : PubMed/NCBI
33	Del Prete SA, Maurer LH, O’Donnel J, Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 68:1403–1405. 1984.PubMed/NCBI
34	Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 327:516–523. 1992. View Article : Google Scholar : PubMed/NCBI
35	Vertosick FT Jr, Selker RG, Pollack IF and Arena V: The treatment of intracranial malignant glioma using orally administered tamoxifen therapy: preliminary results in a series of ‘failed’ patients. Neurosurgery. 30:897–903. 1992.PubMed/NCBI
36	Narasimhan P: Tamoxifen in the treatment of refractory lymphoma. N Engl J Med. 311:1258–1259. 1984. View Article : Google Scholar : PubMed/NCBI
37	Ferguson PJ, Brisson AR, Koropatnick J and Vincent MD: Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett. 274:279–289. 2009. View Article : Google Scholar : PubMed/NCBI
38	Singh MN, Martin-Hirsch PL and Martin FL: The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monit. 14:RA144–RA148. 2008.PubMed/NCBI
39	Kang Y, Cortina R and Perry RR: Role of c-myc in tamoxifen induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst. 88:279–284. 1996. View Article : Google Scholar : PubMed/NCBI
40	Incles CM, Schultes CM, Kelland LR and Neidle S: Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor 1. Mol Pharmacol. 64:1101–1108. 2003. View Article : Google Scholar
41	Cory S and Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 8:5–6. 2005. View Article : Google Scholar : PubMed/NCBI
42	Korsmeyer SJ, Shutter JR, Veis DJ, et al: Bcl-2/Bax: a rheostat that relgulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332. 1993.PubMed/NCBI
43	Agostinis P, Vantieghem A, Merlevede W and de Witte PA: Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol. 34:221–241. 2002. View Article : Google Scholar : PubMed/NCBI
44	Mandlekar S and Kong AN: Mechanism of tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar
45	Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD and Chen DS: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol. 55:523–531. 1998. View Article : Google Scholar